Core Laboratories Sees Q2 GAAP EPS $0.06-$0.12 vs $0.09 Est; Sees Sales $123.000M-$131.000M vs $127.900M Est

Benzinga Newsdesk www.benzinga.com Neutral 69.7%

Neg 0% Neu 69.7% Pos 0%

Core Laboratories (NYSE:CLB) is looking for Q2 GAAP EPS of $0.06-$0.12 vs $0.09 analyst estimate. sees sales of $123.000 million-$131.000 million vs $127.900 million analyst estimate.